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In the treatment of chronic ectopic atrial tachycardia, 
standard antiarrhythmic therapy has been shown to be 
ineffective in the majority of patients. The intravenous 
and oral effects of two class IC antiarrhythmic drugs, 
encainide and f1ecainide, in five patients with chronic 
ectopic atrial tachycardia were studied using exercise 
testing, 24 hour long-term electrocardiography and pro•
grammed electrical stimulation. All patients had been 
treated unsuccessfully with at least four antiarrhythmic 
drugs. In two patients tachycardia was persistent, and 
in three patients tachycardia occurred intermittently for 
more than 12 hours/day. 
Intravenous encainide and f1ecainide at doses ranging 
from 0.3 to 2.0 mglkg and from 0.5 to 1.5 mglkg body 
Chronic ectopic atrial tachycardia is a rare rhythm disorder, 
especially in adults. Clinically, it may be intermittent, last•
ing for more than half of the day, or persistent, interrupted 
only by single sinus beats. It may have serious sequelae, 
such as cerebrovascular accident 0), congestive heart fail•
ure (2) and death (3). Congestive heart failure has been 
reported to be reversible when a marked slowing of tachy•
cardia rate or even restoration of sinus rhythm can be achieved 
(2). 
A great number of therapeutic regimens have been pro•
posed for the treatment of chronic ectopic atrial tachycardia. 
Administration of antiarrhythmic drugs almost always fails 
to control the arrhythmia (2.4,5). Electrical cardioversion, 
programmed stimulation and overdrive pacing are ineffec•
tive because they suppress the focus for at most a few 
seconds (4,5). Promising new approaches in the treatment 
of these patients are surgical excision and transvenous cath-
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weight, respectively, terminated atrial ectopic tachycar•
dia in all patients. Oral encainide, 150 to 225 mg/day, 
completely suppressed ectopic atrial activity in four pa•
tients during a mean follow-up period of 8 ± 3 months. 
In the remaining patient encainide markedly reduced 
the number of episodes of tachycardia. In three patients 
encainide had to be withdrawn because of intolerable 
side effects. These patients were well controlled with oral 
f1ecainide, 200 to 300 mg/day, without side effects. 
On the basis of these results, the efficacy of encainide 
and f1ecainide in the treatment of chronic ectopic atrial 
tachycardia appears to be not drug-specific but rather 
a general class IC property. 
(J Am Coli CardioI1986;7:1121-6) 
eter ablation of the focus (5). Both procedures may defin•
itively cure the patient, but failures have been reported (5). 
Recently, it has been shown that encainide, a class IC 
antiarrhythmic drug (6), is highly effective in patients with 
incessant supraventricular tachycardia (7). We studied the 
short- and long-term effects of two class IC antiarrhythmic 
agents, encainide and flecainide, in patients with chronic 
ectopic atrial tachycardia. Our aim was to elucidate whether 
a favorable effect of encainide on this arrhythmia is drug 
specific or due to a uniform response of ectopic activity to 
class IC antiarrhythmic drugs. 
Methods 
Clinical data. Five patients (two men and three women) 
with a mean age of 37 years were studied (Table I). All 
had symptomatic chronic ectopic atrial tachycardia. In each 
patient the arrhythmia had been refractory to at least four 
antiarrhythmic drugs, including amiodarone and verapamil. 
At the time of study all drugs had been withdrawn for at 
least three half-lives. Two-dimensional echocardiography 
showed an enlarged left ventricular end-diastolic diameter 
of 60 mm in Patient 3 and 65 mm in Patient 2, with mod•
erately depressed global left ventricular contractility in boHl. 
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Table 1. Clinical Data in Five Patients With Chronic Ectopic 
Atrial Tachycardia 
NYHA DuratIOn (yr) 
Age (yr) FunctIOnal Cardiothoracic of 
Case & sex Class Ratio Tachycardia 
I 48M II 0.4 ~ 5 
2 45F III 0.6 ~ 20 
3 23F III 0.6 ~ 7 
4 48M II 0.4 ~ II 
5 22F I 0.5 ~ 18 
NYHA = New York Heart Association. 
These patients had a cardiothoracic ratio of 0.6 each; in all 
other patients no signs of organic heart disease were ob•
served. Routine laboratory examinations revealed no ab•
normalities in any patient. 
In all patients 12 lead electrocardiography, symptom•
limited bicycle exercise testing according to a modified Bruce 
protocol and 24 hour ambulatory electrocardiographic (Hol•
ter) monitoring were performed before drug administration. 
Electropbysiologic study. After informed written con•
sent was obtained, an electrophysiologic study was per•
formed according to a standard protocol (8). In each patient 
four catheters were passed through the femoral veins using 
the Seldinger technique. Quadripolar catheters were placed 
in the lateral high right atrium in all patients, in the coronary 
sinus in four and in the left atrium through a patent foramen 
ovale in one patient. Two bipolar catheters were positioned, 
one across the tricuspid valve to record the His bundle 
electrogram, and another in the apex of the right ventricle. 
A Siemens 16 channel electrocardiograph was used for con•
tinuous display and recording of the endocardial electro•
grams and of at least three body surface electrocardiograms 
at a paper speed of 100 mm/s. A Biotronik stimulator (ERA•
S-HIS) was used to deliver rectangular pulses with a duration 
of 1 ms and a constant current of twice diastolic threshold. 
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In three patients with intermittent tachycardia (Cases 1, 
4 and 5) single and double right and left atrial and right 
ventricular extrastimuli were delivered during sinus rhythm 
and at two different paced cycle lengths (510 and 440 ms), 
The right and left atria were also paced at increasing rates 
up to a maximal rate of 250 beats/min to induce tachycardia. 
If tachycardia could not be induced, isoproterenol was ad•
ministered intravenously until ectopic atrial tachycardia oc•
curred spontaneously or sinus rate had increased by 20%. 
When tachycardia had not occurred spontaneously during 
isoproterenol infusion, the stimulation protocol to induce 
tachycardia was repeated at the increased sinus rate, 
During tachycardia. mapping was performed to localize 
the origin of ectopic atrial activity. Termination of tachy•
cardia was attempted by single right and left atrial as well 
as right ventricular extrastimuli, which were introduced in 
10 ms decrements after every eighth beat. In addition, both 
atria were paced for overdrive suppression at various rates 
exceeding the rate of tachycardia. 
Intravenous encainide, During the electrophysiologic 
study patients received intravenous encainide at a rate of 10 
mg/min until ectopic activity was completely suppressed or 
until a maximal dose of2.0 mg/kg body weight was reached. 
Stimulation studies to initiate atrial tachycardia were then 
repeated as described earlier. 
With one stimulation catheter remaining in the high right 
atrium after the initial study, all patients were restudied 2 
days later in a drug-free state. If sinus rhythm was dominant, 
atrial tachycardia was induced as during the initial study. 
Then all patients received intravenous ftecainide at a rate 
of 10 mg/min under continuous six lead (V 1 to V 6) electro•
cardiographic control until tachycardia was terminated or a 
maximal dose of 1.5 mg/kg was reached. 
Electropbysiologic data. The electrocardiographic and 
electrophysiologic data of ectopic atrial tachycardia are listed 
in Tables 2 and 3. The electrophysiologically determined 
Table 2. Long-Term Electrocardiographic, Exercise Electrocardiographic and Electrophysiologic Data in Five Patients 
With Chronic Ectopic Atrial Tachycardia 
Intravenous Dose Resulting in 
Chronic Ectopic Atrial Tachycardia Tennination of Tachycardia 
Long-Tenn Exercise Origin of Ectopic 
(mg/kg) 
Case ECG ECG ActiVIty Mode of Initiation Encainide Flecainide 
Intennittent Inducible LA: mid anterior Spontaneous 2.0 1.5 
septally 
2 Persistent Persistent RA: low posterior Persistent 1.5 1.5 
septally 
3 Persistent Persistent RA: mid anterior PerSIstent 0.3 0.5 
septally 
4 Intennittent Inducible RA: low posterior Spontaneous, i.v. 1.0 1.0 
septally isoproterenol 
5 Intennittent Not inducible RA: low mid Spontaneous, rapid 1.0 1.5 
septally atrial pacing 
ECG = electrocardiogram; i.v. = intravenous; LA = left atrium; RA = right atrium. 
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Table 3. Conduction Intervals During Chronic Ectopic Atrial Tachycardia in Five Patients 
Interval (ms) 
Case CL (ms) PQ QRS QT AH HV 
530 115 85 305 70 35 
2 440 115 105 360 60 45 
3 440 115/210* 95 320 1001230* 35 
4 310 150 100 320 90 50 
5 530 150 90 310 100 60 
*This patient had dual atrioventricular nodal pathways in anterograde direction. CL = mean cycle length. 
origin of tachycardia was always in concordance with P 
wave configuration in the surface electrocardiogram (9). 
Patient 3 had dual atrioventric~lar (A V) nodal pathways in 
the anterograde direction, responsible for changes of the 
PRiRP interval relation during tachycardia (Fig. 1 to 3). In 
Patient 5 intermittent A V nodal block occurred with per•
petuation of tachycardia on the atrial level. In all patients 
the first tachycardia beat showed an atrial activation se•
quence identical to that of the subsequent tachycardia beats. 
In patients with intermittent tachycardia the arrhythmia could 
not be induced by single or double atrial or ventricular 
extrastimuli. In Patient 5 it was initiated by stimulation at 
increasing rates, and in Patient 4 tachycardia was observed 
after intravenous administration of isoproterenol. 
During tachycardia, single atrial extrastimuli introduced 
at decreasing coupling intervals were followed by an atrial 
cycle that became progressively shorter than compensatory, 
The atria could never be activated retrogradely by a single 
ventricular extrastimulus delivered at the time of refracto•
riness of the bundle of His, during either sinus rhythm or 
tachycardia. In all patients atrial pacing at rates exceeding 
the tachycardia rate captured the atria, yet on termination 
of pacing the tachycardia immediately resumed without an 
intervening sinus beat. Termination could not be achieved 
by programmed stimulation from the atria or the right ven•
tricle in any patient. 
Follow-up with oral encainide or ftecainide. All pa•
tients were discharged receiving oral encainide at a dose of 
150 mg/day. Four weeks after initiation of this medication 
Figure 1. Patient 3. Three lead electrocardiogram (V" V2 • V3) 
of ectopic atrial tachycardia. Upper left panel, Ectopic atrial 
tachycardia at a cycle length of 360 ms with a PR interval greater 
than the RP interval. Upper right and lower panels, Continuous 
recording during encainide injection. After administration of 20 
mg intravenously (i. v.), tachycardia cycle length increased to 480 
ms. associated with aPR interval less than the RP interval due to 
a change in anterograde conduction from a slow to a fast atrio•
ventricular nodal pathway. Note the sudden change of tachycardia 
cycle length from 480 to 960 ms, suggesting 2: I exit block of the 
ectopic focus. P wave configuration remained constant until a 
stable sinus rhythm at a cycle length of 700 ms was reestablished 
(arrows indicate change in P wave configuration). 
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Figure 2. Patient 3. Three lead electrocardiogram (VI, V2 , V3) 
of ectopic atrial tachycardia. Upper left panel, ECfopic atrial 
tachycardia at a cycle length of 540 ms showing a PR interval less 
than the RP interval. Upper right panel, After intravenous (i. v.) 
injection of 20 mg of f1ecainide, tachycardia cycle length had 
increased to 660 ms. Lower panel, After administration of 30 mg 
of flecainide, tachycardia is interrupted by single sinus beats before 
restoration of a regular sinus rhythm at a cycle length of 760 ms 
(arrows indicate change in P wave configuration). 
and every 3 months during the follow-up period, 12 lead 
electrocardipgraphy, exercise testing, 24 hour Holter mon•
itoring and routine laboratory examinations were performed. 
Oral drug therapy was considered to be effective if ectopic 
atrial tachycardia was not inducible by exercise testing and 
24 hour Holter monitoring showed a reduction in duration 
of ectopic activity to less than 10% of the day. If the dose 
of 150 mg/day prove~ ineffective, it was increased to a 
maximum of 225 mg/day. Three patients (Cases 1, 3 and 
5) were treated with oral ftecainide, 200 mg/day, after oral 
encainide was withdrawn because of intolerable side effects. 
If tftis dose was ineffective, it was changed to 300 mg/day. 
Follow-up visits were performed as during oral encainide 
therapy. 
Results 
Effect of iDtravenous encainide on chronic ectopic atrial 
tachycardia. In all patients intravenous administration of 
encainide initially led to a gradual increase of tachycardia 





3 a 2: 1 exit block occurred immediately before the onset 
of sinus rhythm (Fig. 1). The doses necessary for termi•
nation ranged from 0.3 to 1.5 mg/kg (Table 2). After drug 
administration ectopic tachycardia was not inducible. 
Effect of oral encainide on chronic ectopic atrial 
tachycardia. During a mean follow-up period of 8 ± 3 
months, two patients (Cases 2 and 4) tolerated oral encainide 
without side effects and showed no recurrence of ectopic 
atrial tachycardia. In Patient 1 the dose of 150 mg/day was 
reduced after 2 weeks of treatment to 100 mg/day because 
of headach,e and nightmares, which the patient related to 
encainide ingestion. At 11 control visit he complained of 
palpitation. Holter monitoring showed reCllrrences of tachy•
cardia lasting for maximally 30 minutes, and tachycardia 
was still inducible on exercise testing. Oral encainide ther•
apy was therefore discontinued. In Patients 3 and 5 encain•
ide, 150 mg/day, completely sllPpressed ectopic atrial tachy•
cardia (Fig. 2), but both' patients complained of intolerable 
orthostasis and blurred vision. Because of these side effects 
the drug was withdrawn. 
Effect of intravenous ftecainide on chronic ectopic atrial 
tachycardia. In all patients ftecainide, at a dOi'>e ranging 
from 0.5 to 1.5 mg/kg (Table 2), led to a gradual slowing 
of tachycardia rate before a stable sinus rhythm was rees•
tablished and ectopic activity was completely suppressed 
(Fig. 3). 
Effect of oral ftecainide on chronic ectopic atrial 
tachycardia. Three patients (Cqses 1, 3 and 5) received 
oral ftecainide during a mean follow-up period of 7 ± 5 
months. In Patient 1 a dose of 200 mg/day reduced the 
lACC Vol 7, No 5 
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duration of ectopic activity from 70 to 40% of the day, as 
shown by Holter monitoring. Atrial tachycardia was still 
inducible by exercise testing. After an increase of the dose 
to 300 mg/day only short episodes of tachycardia with a 
maximal duration of 2 minutes were observed on Holter 
monitoring. Clinically, the patient was free of symptoms. 
Oral flecainide, 200 mg/day, successfully inhibited palpi•
tation in Patient 3. The Holter electrocardiogram showed 
occasional short runs of tachycardia lasting up to 30 seconds. 
However, ectopic activity recurred 9 to 10 hours after drug 
ingestion. Tachycardia was not inducible by exercise test•
ing. This patient, who was initially in New York Heart 
Association functional class III, improved to class II. Patient 
5 did not have any recurrences of atrial tachycardia at an 
oral dose of flecainide, 200 mg/day. Drug-related side ef•
fects were not observed with oral flecainide therapy. 
Discussion 
Differential diagnosis. The diagnosis of chronic ectopic 
atrial tachycardia in our patients was based on the electro•
cardiographic and electrophysiologic data listed earlier. In 
the differential diagnosis of a supraventricular tachycardia 
showing a PR interval shorter than the RP interval, AV 
nodal tachycardia of the "fast-slow" type or A V recipro•
cating tachycardia using retrogradely an accessory pathway 
+ .. ---:- -l 
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Figure 3. Patient 3. Twelve lead electrocardiograms before and 
during oral (p.o.) encainide therapy at a dose of 150 mg/day. The 
electrocardiograms show the same ectopic atrial tachycardia with 
a PR interval greater than the RP interval (left panels) or with a 
PR interval less than the RP interval (middle panels). See text 
for explanation. Sinus rhythm is shown in the right panels (note 
change of P wave configuration)_ 
with a long conduction time must be considered. However, 
apart from the positive findings for atrial tachycardia, none 
of our patients met the criteria for intranodal or extranodal 
reentrant tachycardia (10,11). 
Efficacy of encainide and ftecainide. In our five pa•
tients, the class IC agents encainide and flecainide, admin•
istered intravenously as well as orally, effectively sup•
pressed chronic ectopic atrial tachycardia. Recently it was 
shown in a large number of patients that encainide termi•
nated incessant supraventricular tachycardia due to a variety 
of mechanisms and originating from various sites (7). In 
two of these patients, each with atrial tachycardia, both 
intravenous and oral encainide were successful in termi•
nating and preventing the arrhythmia. Our data support the 
efficacy of encainide in such patients, who are known to be 
refractory to the majority of antiarrhythmic drugs. 
In a patient with incessant atrial tachycardia occurring 
after successful cryoablation of a left-sided accessory path•
way, flecainide suppressed ectopic activity (12). In our study 
1126 KUNZE ET AL. 
CLASS IC AGENTS IN ECTOPIC ATRIAL TACHYCARDIA 
flecainide proved to be as effective as encainide in the treat•
ment of this arrhythmia. We may therefore infer that the 
beneficial effect on chronic ectopic tachycardia of both drugs 
is not drug specific but a general response to class IC an•
tiarrhythmic properties. Class IC agents have been shown 
to slow phase zero of the action potential. but have little or 
no effect on its duration (13). 
Mechanism of drug action. Encainide as well as fle•
cainide have been reported to depress automaticity of ectopic 
pacemakers significantly in in vitro studies (13,14). 
Suppression of ectopic atrial automaticity may also explain 
the efficacy of these drugs in patients with chronic ectopic 
atrial tachycardia. The increase in tachycardia cycle length 
during intravenous drug administration may give evidence 
for a direct effect on automaticity. Another drug mechanism 
that may also be in effect is exit block formation between 
the ectopic focus and the adjacent atrial tissue. During in•
travenous injection of encainide in two patients, a sudden 
increase of tachycardia cycle length to twice the previous 
value was observed. This observation is more consistent 
with the occurrence of a 2: 1 exit block than with a depres•
sion of automaticity. 
Side effects. Side effects have been observed with oral 
encainide therapy (7,8). Two of our five patients developed 
blurred vision, headache and orthostasis, necessitating the 
discontinuation of encainide therapy. Another patient com•
plained of frequent nightmares that disappeared after with•
drawal of the drug. The high incidence in our patients of 
intolerable encainide-related side effects. despite commonly 
used dosage, is not understood. All three patients received 
flecainide, which was well tolerated by all. Previously un•
recognized atrial or ventricular arrhythmias were not in•
duced by either drug. 
Clinical implications. Chronic ectopic atrial tachycar•
dia is a rare rhythm disorder that may have serious sequelae. 
The therapeutic efficacy of encainide and flecainide shown 
by our study is of clinical importance to patients with this 
disorder, and indicates that medical treatment with class IC 
drugs in such patients offers an alternative to surgery or 
catheter ablation. 
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